#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16838	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2066	802.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1416	1416	C	925	C,T,G	910,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16838	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2066	802.6	0	HET	.	.	.	C260T	.	260	260	C	492	492	C	883	C,T	679,151	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31246	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3453	894.6	0	.	n	.	0	T695C	SNP	695	695	T	953	953	C	923	C,A,T	903,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31246	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3453	894.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1595	1595	A	985	A,G	959,10	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31246	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3453	894.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2229	2229	C	953	C,T	932,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31246	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3453	894.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2855	2855	T	1011	T,C	960,33	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31246	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3453	894.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2303	2303	A	959	A	950	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2262	folP	852	852	100.0	folP.l15.c4.ctg.1	1555	143.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1067	1069	AGC	204;208;207	A;G;C	201;205;205	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6264	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3355	184.7	1	SNP	p	S91F	0	.	.	271	273	TCC	528	530	TCC	220;221;229	T;C;C	215;215;225	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6264	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3355	184.7	1	SNP	p	D95N	0	.	.	283	285	GAC	540	542	GAC	231;233;233	G,A;A;C,T	224,1;225;227,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6264	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3355	184.7	1	SNP	p	D95G	0	.	.	283	285	GAC	540	542	GAC	231;233;233	G,A;A;C,T	224,1;225;227,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2004	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1363	145.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	455	457	ACC	211;212;211	A,G,C;C;C,A	188,9,1;210;208,1	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2004	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1363	145.8	0	.	p	.	0	R44H	NONSYN	130	132	CGC	470	472	CAC	214;211;213	C;A,G;C	207;191,7;208	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2004	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1363	145.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	653	655	CAC	274;276;275	C,T;A,C;C	265,6;264,1;269	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2004	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1363	145.8	1	SNP	p	G45D	0	.	.	133	135	GGC	473	475	GGC	212;211;212	G;G,A;C	207;198,6;207	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1046	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c17.ctg.1	933	111.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5702	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2898	194.4	1	SNP	p	D86N	0	.	.	256	258	GAC	519	521	GAC	243;243;244	G,A;A;C	236,1;229;238	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5702	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2898	194.4	1	SNP	p	S87I	0	.	.	259	261	AGT	522	524	AGT	242;244;244	A,C;G;T	229,3;238;233	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5702	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2898	194.4	1	SNP	p	S87R	0	.	.	259	261	AGT	522	524	AGT	242;244;244	A,C;G;T	229,3;238;233	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5702	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2898	194.4	1	SNP	p	S87W	0	.	.	259	261	AGT	522	524	AGT	242;244;244	A,C;G;T	229,3;238;233	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5702	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2898	194.4	1	SNP	p	S88P	0	.	.	262	264	TCC	525	527	TCC	241;242;238	T;C;C	233;234;233	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4666	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2580	178.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1492	1494	GGC	226;223;220	G;G;C	222;219;213	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2373	180.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1295	1297	GCA	273;273;275	G;C,G;A,C	262;266,1;268,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2373	180.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1298	1300	ATC	279;278;279	A;T;C,T,G	275;274;272,1,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2373	180.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1310	1312	GTG	279;277;273	G,A;T,C;G,C	271,1;265,1;269,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2373	180.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1310	1312	GTG	279;277;273	G,A;T,C;G,C	271,1;265,1;269,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2373	180.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1814	1816	ACC	202;202;205	A;C;C	193;199;202	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2373	180.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1868	1870	GCG	197;197;196	G;C,G;G	183;166,1;186	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2373	180.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1868	1870	GCG	197;197;196	G;C,G;G	183;166,1;186	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2373	180.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1991	1993	GGC	149;144;144	G,A;G;C,T	144,1;139;137,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2373	180.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2000	2002	GGC	137;135;133	G,A;G;C,T	131,1;131;125,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2373	180.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2018	2020	CCG	118;119;117	C,G,T;C;G	109,2,1;110;101	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6416	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3253	195.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2784	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1753	156.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	536	536	C	189	C	171	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	360	porB1a	984	309	91.05	porB1a.l6.c30.ctg.1	1338	24.6	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1051	1053	AAT	25;25;25	A;A;T	25;25;25	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	360	porB1a	984	309	91.05	porB1a.l6.c30.ctg.1	1338	24.6	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1054	1056	AAT	25;25;25	A;A;T	25;25;25	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	360	porB1a	984	309	91.05	porB1a.l6.c30.ctg.1	1338	24.6	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1066	1068	GTT	23;23;23	G;T;T	23;23;23	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	360	porB1a	984	309	91.05	porB1a.l6.c30.ctg.1	1338	24.6	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1078	1080	GCA	21;21;22	G;C;A	20;21;22	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	360	porB1a	984	309	91.05	porB1a.l6.c30.ctg.1	1338	24.6	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1101	1103	GTA	18;18;18	G;T;A	18;18;18	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	360	porB1a	984	309	91.05	porB1a.l6.c30.ctg.1	1338	24.6	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1113	1113	G	17	G	16	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3242	porB1b	1035	1035	95.74	porB1b.l15.c4.ctg.1	1528	208.6	0	.	p	.	0	F135L	NONSYN	403	405	TTT	658	660	CTT	231;232;228	C,T,G;T;T,G	218,4,2;222;219,2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3242	porB1b	1035	1035	95.74	porB1b.l15.c4.ctg.1	1528	208.6	0	.	p	.	0	R143G	NONSYN	427	429	AGA	682	684	GGA	231;232;233	G,A,C;G,A;A	222,4,3;228,3;224	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3242	porB1b	1035	1035	95.74	porB1b.l15.c4.ctg.1	1528	208.6	0	.	p	.	0	G189S	NONSYN	565	567	GGC	820	822	AGC	262;261;265	AG,A;G,A;C	251,1;252,4;261	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3242	porB1b	1035	1035	95.74	porB1b.l15.c4.ctg.1	1528	208.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	886	886	T	250	T	238	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3242	porB1b	1035	1035	95.74	porB1b.l15.c4.ctg.1	1528	208.6	1	SNP	p	G120K	0	.	.	358	360	GGT	613	615	GGT	236;232;229	G,A,T;G,A;T,G	228,1,1;228,1;217,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3242	porB1b	1035	1035	95.74	porB1b.l15.c4.ctg.1	1528	208.6	1	SNP	p	A121N	0	.	.	361	363	GCC	616	618	GCC	230;232;231	G,A;C,A;C	225,1;229,1;221	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3242	porB1b	1035	1035	95.74	porB1b.l15.c4.ctg.1	1528	208.6	1	SNP	p	A121D	0	.	.	361	363	GCC	616	618	GCC	230;232;231	G,A;C,A;C	225,1;229,1;221	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11500	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4872	233.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1979	1981	AAT	246;246;246	A,C;A;T	239,5;243;244	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1346	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1112	119.6	1	SNP	p	V57M	1	.	.	169	171	ATG	597	599	ATG	235;240;242	A;T;G	233;235;238	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
